BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32026657)

  • 21. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
    Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y
    Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Lertkhachonsuk AA; Hanvoravongchai P
    J Reprod Med; 2016; 61(5-6):230-4. PubMed ID: 27424364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
    Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
    Mao Y; Wan X; Lv W; Xie X
    Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.
    Alazzam M; Tidy J; Osborne R; Coleman R; Hancock BW; Lawrie TA
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD008891. PubMed ID: 26760424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?
    Essel KG; Bruegl A; Gershenson DM; Ramondetta LM; Naumann RW; Brown J
    Gynecol Oncol; 2017 Jul; 146(1):74-80. PubMed ID: 28473205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of drug resistant gestational trophoblastic neoplasia.
    Patel SM; Desai A
    J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etoposide-Actinomycin as Salvage Regimen for the Treatment of Nonmetastatic and Low-Risk Metastatic Gestational Trophoblastic Neoplasia: Experience at the Philippine General Hospital.
    Nevado-Gammad MS; Soriano-Estrella AL
    Int J Gynecol Cancer; 2016 Jun; 26(5):977-83. PubMed ID: 27206220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
    Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
    Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 30 years' experience in the treatment of low-risk gestational trophoblastic neoplasia in Hungary.
    Fülöp V; Szigetvári I; Szepesi J; Végh G; Bátorfi J; Nagymányoki Z; Török M; Berkowitz RS
    J Reprod Med; 2010; 55(5-6):253-7. PubMed ID: 20626182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
    Byun SW; Park TC; Bae SN
    Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.
    Han SN; Amant F; Leunen K; Devi UK; Neven P; Berteloot P; Vergote I
    Gynecol Oncol; 2012 Oct; 127(1):47-50. PubMed ID: 22705360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
    Jareemit N; Therasakvichya S; Freitas F; Paiva G; Ramírez LAC; Berkowitz RS; Horowitz NS; Maestá I; Fülöp V; Braga A; Elias KM
    Gynecol Oncol; 2023 Mar; 170():114-122. PubMed ID: 36682089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
    Baptista AM; Belfort P
    Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasm.
    Anantharaju AA; Pallavi VR; Bafna UD; Rathod PS; R VC; K S; Kundargi R
    Int J Gynecol Cancer; 2019 Mar; 29(3):547-553. PubMed ID: 30700567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia].
    Wu XD; Chen LL; Shen T; Chen SS; Chen QQ; Qin JL; Fu YF; Lü WG
    Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(23):1769-1772. PubMed ID: 28647996
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.